AUDIO: Stirling Products Limited ASX:STI Excellence In Biotechnology Investment - Dr Calvin London, MD
Sydney, June 24, 2008 (ABN Newswire) - Stirling Products Limited Excellence in Biotechnology Investment - Dr Calvin London, MD, Stirling Products Ltd; Stirling Products Limited (ASX: STI) present the following audio webcast regarding "Excellence in Biotechnology Investment - Dr Calvin London, MD, Stirling Products Ltd". You may also download this audio webcast to your computer or portable audio player.
Broadcaster: Stirling Products Limited (ASX: STI)
Broadcast Title: Excellence in Biotechnology Investment - Dr Calvin London, MD, Stirling Products Ltd
Broadcast Type: Audio stream
Audio webcast Link:
Listen to the Audio stream and view the announcement for Stirling Products Limited (ASX: STI) below.
http://abnnewswire.net/vlnk/55985082
This Audio Cast is based on streaming audio sent in compressed form over the internet and displayed as it arrives. You do not have to wait for the whole file to be downloaded before you can hear it, instead the media is sent in a continuous stream and is played immediately as it reaches your computer. Please note that during live broadcasts there can be a delay of approximately 1-2 minutes, depending on traffic through your Internet Service Provider.
Minimum requirement for playing the multimedia links are; at least a 28.8k modem and sufficient memory and hard disk space to run Windows Media Player or Real Player. In addition, some media links contain material requiring the ability to run Flash Multimedia.
About STIRLING PRODUCTS LIMITED
Stirling Products is developing patented animal growth agents that increase meat production, therefore improving the production efficiency of livestock animals, while decreasing fat accumulation for the benefit of consumers. The Stirling growth agents are under development for swine, poultry, cattle and sheep for global markets and are being positioned to take a major role in reducing the global use of antibiotics and steroid hormones in livestock. Stirling is also developing veterinary medications for heaves in horses through its joint venture in Europe (Pulmovet ApS, www.pulmovet.com) and an obesity treatment in companion animals.
Stirling Products recently acquired a Canadian company Progressive BioActives Incorporated (PBI) under its North American subsidiary, Stirling Products NA Inc. PBI is part of the Bioscience cluster established on located Prince Edward Island, Canada. PBI's lead product ProVale, is the latest high purity beta glucan extract that has been designed as an alternative tool for sustainable livestock management in face of increasing viral disease challenges where antibiotics have no or limited application. ProVale is available for targeted applications in swine, poultry and farmed aquaculture with a future focus on further developing applications for companion animals (e.g. horses, dogs, cats and reptiles).
